Enterprise Value
54.23M
Cash
142.8M
Avg Qtr Burn
-7.582M
Short % of Float
4.48%
Insider Ownership
2.01%
Institutional Own.
60.64%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Reproxalap Details Dry eye syndrome | NDA Resubmission | |
ADX-2191 (methotrexate injection (DHFR inhibitor)) Details Eye disease , Proliferative vitreoretinopathy, Rare diseases, Primary Vitreoretinal Lymphoma, Retinitis Pigmentosa | NDA FDA meeting | |
Reproxalap (ADX-102) Details Rare diseases, Rare genetic disease, Allergic conjunctivitis | Phase 3 Update | |
ADX-629 Details Alcoholic hepatitis, Liver disease | Phase 2 Data readout | |
ADX-629 Details Sjögren-Larsson Syndrome | Phase 2 Update | |
ADX-629 Details Chronic cough | Phase 2 Update | |
ADX-629 Details Idiopathic Nephrotic Syndrome | Phase 2a Data readout | |
ADX-629 Details Atopic dermatitis | Phase 2a Update |